Does Extended Use of Clopidogrel-Based Dual Anti-Platelet Therapy Increase the Risk of Gastrointestinal Bleeding?

BACKGROUND: Clopidogrel-based dual anti-platelet therapy (CDAPT) has shown significant benefits in the management of coronary artery disease (CAD), up to 1-year duration. Gastrointestinal bleeding (GIB) is one of the limiting factors for prolonged use of CDAPT. METHODS: We identified all patients ta...

Descripción completa

Detalles Bibliográficos
Autores principales: Abbas, Hafsa, Kumar Nayudu, Suresh, Ravi, Madhavi, Saad, Muhammad, Bathini, Kashyap, Ravi, Pranav, Roy, Swathi, Arya, Divya, Chilimuri, Sridhar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7433374/
https://www.ncbi.nlm.nih.gov/pubmed/32864025
http://dx.doi.org/10.14740/gr1285

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7433374/
https://www.ncbi.nlm.nih.gov/pubmed/32864025
http://dx.doi.org/10.14740/gr1285

Ejemplares similares